ClinVar Miner

Submissions for variant NM_025137.4(SPG11):c.3075dup (p.Glu1026fs)

dbSNP: rs312262752
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 17
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Genomic Research Center, Shahid Beheshti University of Medical Sciences RCV000001176 SCV000784243 pathogenic Hereditary spastic paraplegia 11 2018-03-05 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000001176 SCV000823844 pathogenic Hereditary spastic paraplegia 11 2024-11-05 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Glu1026Argfs*4) in the SPG11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG11 are known to be pathogenic (PMID: 19105190, 20110243, 22154821, 26556829). This variant is present in population databases (rs312262752, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with autosomal recessive juvenile amyotrophic lateral sclerosis, and hereditary spastic paraplegia (PMID: 18067136, 19105190, 19194956, 20110243, 27071356, 27084228, 28991695). It has also been observed to segregate with disease in related individuals. This variant is also known as c.3076insA, c.3076_3077insA, and c.3075_3076insA,. ClinVar contains an entry for this variant (Variation ID: 1117). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Paris Brain Institute, Inserm - ICM RCV000001176 SCV001451255 pathogenic Hereditary spastic paraplegia 11 criteria provided, single submitter clinical testing
Kariminejad - Najmabadi Pathology & Genetics Center RCV001813929 SCV001755384 pathogenic Abnormal central motor function 2021-07-10 criteria provided, single submitter clinical testing
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden RCV002247231 SCV002010947 pathogenic not provided 2021-11-03 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV002247231 SCV002520053 pathogenic not provided 2021-12-10 criteria provided, single submitter clinical testing PM2, PM3, PS4_moderate, PVS1_strong
Genome-Nilou Lab RCV001762029 SCV002764002 pathogenic Amyotrophic lateral sclerosis type 5 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV000001176 SCV002764003 pathogenic Hereditary spastic paraplegia 11 criteria provided, single submitter clinical testing
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV000001176 SCV003761347 pathogenic Hereditary spastic paraplegia 11 2023-01-25 criteria provided, single submitter curation The homozygous p.Glu1026ArgfsTer4 variant in SPG11 was identified by our study in two siblings with spastic paraplegia. The p.Glu1026ArgfsTer4 variant in SPG11 has been previously reported in 17 unrelated individuals with hereditary spastic paraplegia 11 (PMID: 29983107, PMID: 35906604, PMID: 35348942, PMID: 32383541, PMID: 18067136, PMID: 19105190, PMID: 19194956, PMID: 20110243, PMID: 27071356, PMID: 27084228, PMID: 28991695) and segregated with disease in 7 affected members from 3 families (PMID: 35348942, PMID: 19194956, PMID: 20110243), but has been identified in 0.01% (3/21626) of European (Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs312262752). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of these 17 unrelated affected individuals (PMID: 29983107, PMID: 35906604, PMID: 35348942, PMID: 32383541, PMID: 18067136, PMID: 19105190, PMID: 19194956, PMID: 20110243, PMID: 27071356, PMID: 27084228, PMID: 28991695), 8 were homozygotes (PMID: 19194956, PMID: 20110243, PMID: 32383541, PMID: 18067136) and 8 were compound heterozygotes who carried pathogenic or likely pathogenic variants in trans (PMID: 29983107, PMID: 35906604, PMID: 35348942, PMID: 32383541, PMID: 19105190, ClinVar ID: 41313; PMID: 27071356 , PMID: 27084228, PMID: 28991695), which increases the likelihood that the p.Glu1026ArgfsTer4 variant is pathogenic. This variant has also been reported in ClinVar (Variation ID: 1117) and has been interpreted as pathogenic by multiple submitters. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1026 and leads to a premature termination codon 4 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the SPG11 gene is an established disease mechanism in autosomal recessive SPG11-related neurologic disease. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive spastic paraplegia 11. ACMG/AMP Criteria applied: PVS1, PM2_Supporting, PM3_VeryStrong, PP1_Moderate (Richards 2015).
Neurogenomics Lab, Neuroscience Institute, University Of Cape Town RCV000001176 SCV003930340 pathogenic Hereditary spastic paraplegia 11 2024-05-22 criteria provided, single submitter research PM2_supporting: the highest population allele frequency in gnomAD v4.0 is 0.0001095 (0.001%; 7/63948 alleles in European Finnish population) and in gnomAD v3.1.2 is 0.00002413 (0.002%; 1/ 41440 alleles in African/African American population) and the variant is absent from an internal database of 1074 control alleles. PP1_moderate: variant segregates with 2 informative meioses in 1 family. PM3_strong: 3 points awarded for 2 homozygous occurrences, 2 observations with pathogenic variant but phase unknown and 1 observation with pathogenic variant confirmed in trans. PVS1_met: null variant (nonsense or frameshift variant, predicted to undergo NMD, exon is present in biologically-relevant transcript) in a gene where LOF is a known mechanism of disease. Sequencing funded by the International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD): https://www.ucl.ac.uk/genomic-medicine-neuromuscular-diseases/.
GeneDx RCV002247231 SCV004022990 pathogenic not provided 2023-01-24 criteria provided, single submitter clinical testing Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28991695, 29983107, 32383541, 27071356, 35254204, 20110243, 18067136)
CeGaT Center for Human Genetics Tuebingen RCV002247231 SCV004136525 pathogenic not provided 2022-10-01 criteria provided, single submitter clinical testing SPG11: PVS1, PM2, PM3, PS4:Moderate
Clinical Genetics Laboratory, Skane University Hospital Lund RCV002247231 SCV005198341 pathogenic not provided 2022-07-13 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV005007806 SCV005637903 pathogenic Amyotrophic lateral sclerosis type 5; Hereditary spastic paraplegia 11; Charcot-Marie-Tooth disease axonal type 2X 2024-03-21 criteria provided, single submitter clinical testing
OMIM RCV000001176 SCV000021326 pathogenic Hereditary spastic paraplegia 11 2009-10-05 no assertion criteria provided literature only
GeneReviews RCV000001176 SCV000058141 not provided Hereditary spastic paraplegia 11 no assertion provided literature only
PreventionGenetics, part of Exact Sciences RCV004748491 SCV005350127 pathogenic SPG11-related disorder 2024-03-05 no assertion criteria provided clinical testing The SPG11 c.3075dupA variant is predicted to result in a frameshift and premature protein termination (p.Glu1026Argfs*4). This variant has been reported in the homozygous or compound heterozygous state in individuals with hereditary spastic paraplegia (see for example, Balicza et al. 2016. PubMed ID: 27084228; Khani et al. 2020. PubMed ID: 32383541; Schneider-Gold et al. 2017. PubMed ID: 28991695). This variant is reported in 0.014% of alleles in individuals of European (Finnish) descent in gnomAD. Frameshift variants in SPG11 are expected to be pathogenic. This variant is interpreted as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.